Nebulized LAMA/LABA Combination (TD-0903)
COPD (Maintenance Treatment)
Phase 2Active (Status Unclear)
Key Facts
Indication
COPD (Maintenance Treatment)
Phase
Phase 2
Status
Active (Status Unclear)
Company
About Theravance Biopharma
Theravance Biopharma is a commercial-stage biotech focused on transforming treatment for serious respiratory diseases through organ-selective medicines. Its core achievement is the FDA approval and commercialization of YUPELRI® (revefenacin) for COPD, validating its multivalent pharmacology platform. The company's strategy involves leveraging this platform to advance a pipeline of targeted respiratory therapeutics while managing commercial execution through a partnership with Viatris.
View full company profileTherapeutic Areas
Other COPD (Maintenance Treatment) Drugs
| Drug | Company | Phase |
|---|---|---|
| YUPELRI® (revefenacin) | Theravance Biopharma | Approved |